Therapy News and Research

RSS

Glutamate identified as predictor of disease progression in multiple sclerosis

UCSF researchers have identified a correlation between higher levels of glutamate, which occurs naturally in the brain as a byproduct of metabolism, and greater disease burden in multiple sclerosis patients.

29 Apr 2009

DNA "barcodes" used to map mosquito species in West Africa that spread lymphatic filariasis

New biotechnologies that allow scientists to quickly and accurately distinguish species based on a simple DNA analysis are being creatively deployed for the first time in the war against a major global disease.

29 Apr 2009

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

29 Apr 2009

Wyeth's Conbriza (bazedoxifene) approved in Europe for postmenopausal osteoporosis

Wyeth Pharmaceuticals has announced that the European Commission has granted marketing authorization for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.

27 Apr 2009

Voice response system useful for monitoring anticoagulant patients

Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff, found a study by Ottawa researchers in CMAJ.

27 Apr 2009

$Prostate cancer therapy increases risk of fractures and cardiovascular-related death$

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.

27 Apr 2009

Research sheds new light on causes of sepsis

New research from Lucile Packard Children's Hospital and the Stanford University School of Medicine is helping physicians unravel the cause of a deadly and mysterious bowel disease that strikes medically fragile newborn babies.

27 Apr 2009

Discovery of novel protein which, when over-expressed, leads to a dramatic increase in the generation of A-beta

A defining hallmark of Alzheimer's disease is the accumulation of the amyloid beta protein (A-beta), otherwise known as "senile plaques," in the brain's cortex and hippocampus, where memory consolidation occurs.

27 Apr 2009

Meditation may temporarily boost visuospatial abilities

Meditation has been practiced for centuries, as a way to calm the soul and bring about inner peace.

27 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

AUA counters mainstream recommendations with new best practice statement on PSA testing

The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.

27 Apr 2009

Different treatment options in chronic coronary artery disease

Sometimes cardiologists and cardiac surgeons can agree! There is often disagreement between the professions of cardiology and cardiac surgery about the proper therapy for coronary artery disease (CAD)-and this can harm the patient.

27 Apr 2009

Green nanotechnology from tea

Researchers from the University of Missouri-Columbia report in the Journal of Materials Chemistry that chemicals in tea are the best yet discovered to make consistent, biologically safe gold nanoparticles. More importantly, these gold nanoparticles show promising anticancer properties.

27 Apr 2009

Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells

Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug-resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.

27 Apr 2009

Combination of vitamin E, selenium and soy does not prevent prostate cancer

The combination therapy of vitamin E, selenium and soy does not prevent the progression from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer, according to the new research presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).

26 Apr 2009

Scientists improve immune response to cancer

A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.

26 Apr 2009

Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C

Pharmasset, Inc. and Roche have announced that the first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment of chronic hepatitis C (HCV).

26 Apr 2009

Active surveillance can offer prostate cancer patients more individualized patient care

Active surveillance may be a viable option for some men, but reclassification of disease risk over time is imperative to ensure outcomes, according to researchers in Toronto, who will present these criteria during the 104th Annual Scientific Meeting of the American Urological Association (AUA).

26 Apr 2009

Autologous muscle-derived cells may treat stress urinary incontinence

Researchers have confirmed that transplanting autologous muscle-derived cells (AMDC) into the bladder is safe at a wide range of doses and significantly improves symptoms and quality of life in patients with stress urinary incontinence.

26 Apr 2009

Women warned about risks of alternative menopause treatments

Scientists at the University of Adelaide in South Australia are warning women about the use of 'alternative' menopause treatments because many have not been properly tested.

26 Apr 2009

Therapy News and Research

Glutamate identified as predictor of disease progression in multiple sclerosis

DNA "barcodes" used to map mosquito species in West Africa that spread lymphatic filariasis

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

Wyeth's Conbriza (bazedoxifene) approved in Europe for postmenopausal osteoporosis

Voice response system useful for monitoring anticoagulant patients

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Research sheds new light on causes of sepsis

Discovery of novel protein which, when over-expressed, leads to a dramatic increase in the generation of A-beta

Meditation may temporarily boost visuospatial abilities

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

AUA counters mainstream recommendations with new best practice statement on PSA testing

Different treatment options in chronic coronary artery disease

Green nanotechnology from tea

Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells

Combination of vitamin E, selenium and soy does not prevent prostate cancer

Scientists improve immune response to cancer

Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C

Active surveillance can offer prostate cancer patients more individualized patient care

Autologous muscle-derived cells may treat stress urinary incontinence

Women warned about risks of alternative menopause treatments

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News